At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Prazosin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reducing Suicidal Ideation Through Treatment of Nightmares-PTSD
In Brief
A Phase 4 clinical trial evaluating Prazosin and Placebo for Post Traumatic Stress Disorder and 2 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Patients with PTSD, and frequent nightmares, and mild-moderate suicidal ideation, who are already taking a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) will be randomized to either prazosin or placebo. The investigators hypothesize that patients receiving prazosin will have a greater reduction in suicidal ideation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedJul 2014
Primary CompletionSep 2017
Study CompletionDec 2017
TodayJul 2026
First PostedJul 24, 2014
Enrollment StartMar 1, 2014
Primary CompletionSep 1, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.9 years ago
Interventions
Prazosindrug
Placebodrug